SCHEMBL12112200

SCHEMBL12112200

Cc1ccc(Cn2c3ncnc4c(ncn4Cc4ccc(CS)cc4)c-3nc2=O)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC29A1 Q99808 2/20 0.46
▸ PDE10A Q9Y233 1/20 0.44
▸ ADORA2A P29274 1/20 0.41
▸ PI4KA P42356 1/20 0.41
▸ PI4K2B Q8TCG2 1/20 0.41
▸ PI4K2A Q9BTU6 1/20 0.41
▸ PI4KB Q9UBF8 1/20 0.41
▸ FGFR1 P11362 4/20 0.39
▸ FGFR4 P22455 4/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE4B Q07343 1/20 0.38
▸ PDE4C Q08493 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12112160 0.94 PDE10A (0.48) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112183 0.92 PDE10A (0.44) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112171 0.90 MEN1 (0.47) SLC29A1PDE10AADORA2AFGFR1FGFR4
SCHEMBL13394067 0.90 SLC29A1 (0.39) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112177 0.89 PDE10A (0.44) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112179 0.89 PDE10A (0.44) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112206 0.89 PDE10A (0.47) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112214 0.89 PDE10A (0.44) SLC29A1PDE10AADORA2API4KAPI4K2B
SCHEMBL12112197 0.89 MEN1 (0.44) SLC29A1PDE10AMEN1CYP1A2CYP3A4
SCHEMBL12112180 0.89 PDE10A (0.44) SLC29A1PDE10AADORA2API4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160319366-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY (US) 2016-11-03 — — US disclosed
US-9322831-B2 DDX3 as a biomarker for cancer and methods related thereto THE JOHNS HOPKINS UNIVERSITY (US) 2016-04-26 — — US disclosed
US-20130281440-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO THE JOHNS HOPKINS UNIVERSITY 2013-10-24 — — US disclosed
US-8518901-B2 Fused diimidazodiazepine compounds and methods of use and manufacture thereof THE JOHNS HOPKINS UNIVERSITY (US) 2013-08-27 — — US disclosed
US-20110275588-A1 Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof HOSMANE, RAMACHANDRA S. 2011-11-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160319366-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO DDX3X, DDB1, DDX24 SLC29A1 2701/4885PDE10A 3839/4885ADORA2A 4578/4885
US-20110275588-A1 Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof IKZF3, AADAC, IKBKE SLC29A1 3265/4885PDE10A 1993/4885ADORA2A 2862/4885
US-20130281440-A1 DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO DDX3X, DDB1, DDX24 SLC29A1 2701/4885PDE10A 3839/4885ADORA2A 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback